|
1
|
Klein AP: Identifying people at a high
risk of developing pancreatic cancer. Nat Rev Cancer. 13:66–74.
2013.PubMed/NCBI View
Article : Google Scholar
|
|
2
|
Kamisawa T, Wood LD, Itoi T and Takaori K:
Pancreatic cancer. Lancet. 388:73–85. 2016.
|
|
3
|
Moutinho-Ribeiro P, Coelho R, Giovannini M
and Macedo G: Pancreatic cancer screening: Still a delusion?
Pancreatology. 17:754–765. 2017.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Rahib L, Smith BD, Aizenberg R, Rosenzweig
AB, Fleshman JM and Matrisian LM: Projecting cancer incidence and
deaths to 2030: The unexpected burden of thyroid, liver, and
pancreas cancers in the United States. Cancer Res. 74:2913–2921.
2014.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2017. CA Cancer J Clin. 67:7–30. 2017.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Talmadge JE and Fidler IJ: AACR centennial
series: The biology of cancer metastasis: Historical perspective.
Cancer Res. 70:5649–5669. 2010.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Pang EJ, Yang R, Fu XB and Liu YF:
Overexpression of long non-coding RNA MALAT1 is correlated with
clinical progression and unfavorable prognosis in pancreatic
cancer. Tumor Biol. 36:2403–2407. 2015.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Li Y, Vandenboom TG II, Wang Z, Kong D,
Ali S, Philip PA and Sarkar FH: miR-146a suppresses invasion of
pancreatic cancer cells. Cancer Res. 70:1486–1495. 2010.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Kamisawa T, Isawa T, Koike M, Tsuruta K
and Okamoto A: Hematogenous metastases of pancreatic ductal
carcinoma. Pancreas. 11:345–349. 1995.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Chaffer CL and Weinberg RA: A perspective
on cancer cell metastasis. Science. 331:1559–1564. 2011.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297.
2004.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Wu G, Li ZH, Jiang P, Zhang X, Xu YQ, Chen
K and Li XW: MicroRNA-23a promotes pancreatic cancer metastasis by
targeting epithelial splicing regulator protein 1. Oncotarget.
8:82854–82871. 2017.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Zhang XJ, Jin Y, Song JL and Deng F:
MiR-373 promotes proliferation and metastasis of oral squamous cell
carcinoma by targeting SPOP. Eur Rev Med Pharmacol Sci.
23:5270–5276. 2019.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Li Y, Zhang H, Dong Y, Fan Y, Li Y, Zhao
C, Wang C, Liu J, Li X, Dong M, et al: MiR-146b-5p functions as a
suppressor miRNA and prognosis predictor in non-small cell lung
cancer. J Cancer. 8:1704–1716. 2017.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Liu C, Jian M, Qi H and Mao WZ:
MicroRNA-495 inhibits proliferation and metastasis and promotes
apoptosis by targeting twist1 in gastric cancer cells. Oncol Res.
27:389–397. 2019.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Qiao G, Li J, Wang J, Wang Z and Bian W:
miR-381 functions as a tumor suppressor by targeting ETS1 in
pancreatic cancer. Int J Mol Med. 44:593–607. 2019.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Zhou Y, Li Z, Ding Y, Zhang P and Wang J:
MicroRNA-340 suppresses pancreatic cancer growth by targeting
BICD2. Pancreatology. 19:30556–30563. 2019.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Yu H, Gao G, Cai J, Song H, Ma Z, Jin X,
Ji W and Pan B: MiR-539 functions as a tumor suppressor in
pancreatic cancer by targeting TWIST1. Exp Mol Pathol. 108:143–149.
2019.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Su R, Dong L, Zou D, Zhao H, Ren Y, Li F,
Yi P, Li L, Zhu Y, Ma Y, et al: MicroRNA-23a, -27a and -24
synergistically regulate JAK1/Stat3 cascade and serve as novel
therapeutic targets in human acute erythroid leukemia. Oncogene.
35:6001–6014. 2016.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Cai S, Chen R, Li X, Cai Y, Ye Z, Li S, Li
J, Huang H, Peng S, Wang J, et al: Downregulation of microRNA-23a
suppresses prostate cancer metastasis by targeting the PAK6-LIMK1
signaling pathway. Oncotarget. 6:3904–3917. 2015.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Wang G, Li B, Fu Y, He M, Wang J, Shen P
and Bai L: miR-23a suppresses proliferation of osteosarcoma cells
by targeting SATB1. Tumour Biol. 36:4715–4721. 2015.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Bloomston M, Frankel WL, Petrocca F,
Volinia S, Alder H, Hagan JP, Liu CG, Bhatt D, Taccioli C and Croce
CM: MicroRNA expression patterns to differentiate pancreatic
adenocarcinoma from normal pancreas and chronic pancreatitis. JAMA.
297:1901–1908. 2007.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Diao H, Ye Z and Qin R: miR-23a acts as an
oncogene in pancreatic carcinoma by targeting FOXP2. J Investig
Med. 66:676–683. 2018.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Liu N, Sun YY, Zhang XW, Chen S, Wang Y,
Zhang ZX, Song SW, Qiu GB and Fu WN: Oncogenic miR-23a in
pancreatic ductal adenocarcinogenesis via inhibiting APAF1. Dig Dis
Sci. 60:2000–2008. 2015.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Tang Z, Geng G, Huang Q, Xu G, Hu H, Chen
J and Li J: Expression of tissue factor pathway inhibitor 2 in
human pancreatic carcinoma and its effect on tumor growth,
invasion, and migration in vitro and in vivo. J Surg Res.
167:62–69. 2011.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Zhai LL, Wu Y, Huang DW and Tang ZG:
Increased matrix metalloproteinase-2 and reduced tissue factor
pathway inhibitor-2 expression correlate with angiogenesis and
early postoperative recurrence of pancreatic carcinoma. Am J Transl
Res. 7:2412–2422. 2015.PubMed/NCBI
|
|
27
|
Zhai LL, Wu Y, Cai CY and Tang ZG:
Upregulated matrix metalloproteinase-2 and downregulated tissue
factor pathway inhibitor-2 are risk factors for lymph node
metastasis and perineural invasion in pancreatic carcinoma. Onco
Targets Ther. 8:2827–2834. 2015.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2012.
|
|
29
|
Hussain H and Chong NF: Combined overlap
extension PCR method for improved site directed mutagenesis. Biomed
Res Int. 2016(8041532)2016.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Meng H, Huang Q, Zhang X, Huang J, Shen R
and Zhang B: MiR-449a regulates the cell migration and invasion of
human non-small cell lung carcinoma by targeting ADAM10. Onco
Targets Ther. 12:3829–3838. 2019.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Tao C, Sun H, Sang W and Li S: miRNA-99a
inhibits cell invasion and migration in liver cancer by directly
targeting HOXA1. Oncol Lett. 17:5108–5114. 2019.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Pan DS, Cao P, Li JJ, Fan D and Song ZQ:
MicroRNA-374b inhibits migration and invasion of glioma cells by
targeting EGFR. Eur Rev Med Pharmacol Sci. 23:4254–4263.
2019.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Zhu LH, Liu T, Tang H, Tian RQ, Su C, Liu
M and Li X: MicroRNA-23a promotes the growth of gastric
adenocarcinoma cell line MGC803 and downregulates interleukin-6
receptor. FEBS J. 277:3726–3734. 2010.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Wang Z, Wei W and Sarkar FH: miR-23a, a
critical regulator of ‘migR’ation and metastasis in colorectal
cancer. Cancer Discov. 2:489–491. 2012.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Huang S, He X, Ding J, Liang L, Zhao Y,
Zhang Z, Yao X, Pan Z, Zhang P, Li J, et al: Upregulation of
miR-23a approximately 27a approximately 24 decreases transforming
growth factor-beta-induced tumor-suppressive activities in human
hepatocellular carcinoma cells. Int J Cancer. 123:972–978.
2008.PubMed/NCBI View Article : Google Scholar
|
|
36
|
He Y, Meng C, Shao Z, Wang H and Yang S:
MiR-23a functions as a tumor suppressor in osteosarcoma. Cell
Physiol Biochem. 34:1485–1496. 2014.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Lu S and Xu Q: MicroRNA-23a inhibits
melanoma cell proliferation, migration, and invasion in mice
through a negative feedback regulation of SDCBP and the MAPK/ERK
signaling pathway. IUBMB Life. 71:587–600. 2019.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Eble JA and Niland S: The extracellular
matrix in tumor progression and metastasis. Clin Exp Metastasis.
36:171–198. 2019.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Chang TT, Thakar D and Weaver VM:
Force-dependent breaching of the basement membrane. Matrix Biol.
57-58:178–189. 2017.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Wang G, Zeng Y, Chen S, Li D, Li W, Zhou
Y, Singer RH and Gu W: Localization of TFPI-2 in the nucleus
modulates MMP-2 gene expression in breast cancer cells. Sci Rep.
7(13575)2017.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Konduri SD, Tasiou A, Chandrasekar N,
Nicolson GL and Rao JS: Role of tissue factor pathway inhibitor-2
(TFPI-2) in amelanotic melanoma (C-32) invasion. Clin Exp
Metastasis. 18:303–308. 2000.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Iochmann S, Bléchet C, Chabot V, Saulnier
A, Amini A, Gaud G, Gruel Y and Reverdiau P: Transient RNA
silencing of tissue factor pathway inhibitor-2 modulates lung
cancer cell invasion. Clin Exp Metastasis. 26:457–467.
2009.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Ma S, Chan YP, Kwan PS, Lee TK, Yan M,
Tang KH, Ling MT, Vielkind JR, Guan XY and Chan KW: MicroRNA-616
induces androgen-independent growth of prostate cancer cells by
suppressing expression of tissue factor pathway inhibitor TFPI-2.
Cancer Res. 71:583–592. 2011.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Andresen MS, Stavik B, Sletten M, Tinholt
M, Sandset PM, Iversen N and Skretting G: Indirect regulation of
TFPI-2 expression by miR-494 in breast cancer cells. Sci Rep.
10(4036)2020.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Chen B, Zhu A, Tian L, Xin Y, Liu X, Peng
Y, Zhang J, Miao Y and Wei J: miR 23a suppresses pancreatic cancer
cell progression by inhibiting PLK 1 expression. Mol Med Rep.
18:105–112. 2018.PubMed/NCBI View Article : Google Scholar
|
